Natrol results
This article was originally published in The Tan Sheet
Executive Summary
Chatsworth, Calif.-based supplement firm's sales increase 9.1% to $6.6 mil. in 2004, with net earnings of $1.9 mil. compared to a $1.5 mil. loss from discontinued operations in 2003. Diet products and "core items" such as Ester-C yielded strong results during the year, offsetting "softness in our raw material business as well as essentially flat sales in our sports nutrition business," President & Chairman Elliot Balbert reported March 15. Natrol recorded flat sales and a net loss of $402,000 in the fourth quarter...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.